Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Irel…
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price45.97 USD
Fair value49.11
Ethical score70.0/100
Our investment reviews on this name
2026-08-21Read Markdown48.37-5.0% to today ✓
2026-07-02Read Markup44.28+3.8% to today ✓
Our analytic regime reads on this name, dated and marked against today's price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Alkermes plc holds its Markdown at $45.97. Consolidating, no directional conviction, held for 26 days.
As held on the ledger · 2026-09-11
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 26 days
Price at the screen
$45.97
Valuation
120.97 trailing · 25.14 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.26
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.81%
Below 33%
Interest-bearing debt is just 2.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
8.03%
Below 33%
Cash held in interest-bearing accounts and securities is 8.0% of assets, under the one-third limit.
Pass
Receivables
26.43%
Below 49%
Money owed to the company is 26.4% of assets, under the 49% limit.
Pass
Revenue purity
3.07%
Below 5%
Only 3.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-11 screen. The gold marker is the market price at the same screen. A 6.8% margin of safety to the base estimate.
Third-party analyst targets: 17 covering, consensus Buy. The average target sits +26% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-11 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Fast growing drug maker commands a premium price
A patient in need of better mental health or addiction treatments gets the medicine from Alkermes research pipeline. The company is posting 28% revenue growth and clearing the ethical screen with a clean bill. Yet the shares sit at 52.72 dollars against our 42.02 dollar fair value, a 20% stretch that leaves no margin of safety.
That valuation looks even richer next to a 32 times forward earnings multiple, a 10% profit margin and just 9% return on equity. Analyst targets cluster around 48 dollars, below where the stock trades today. Growth is real but the price already bakes in more optimism than the returns on capital can support.
High multiples on modest profitability often signal the risk of disappointment if pipeline delivery slows or competition intensifies. The business clears ethics but fails on price. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ALKS trades on Nasdaq (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-21Markdown · changed$48.37-8.3%Entry 6
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
2026-07-21Markup$52.72+19.1%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 19.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
2026-07-18Markup$44.28+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
2026-07-17Markup$44.28+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 42%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (16 analysts) rates it buy, with a mean price target of $45.
2026-07-03Markup$44.28+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markup$44.28Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
